cll: optimal approaches for patients with deletion 17p
Published 7 years ago • 1.6K plays • Length 21:05Download video MP4
Download video MP3
Similar videos
-
19:42
treatment options for the young cll patient with deletion 17p: do they need a different approach?
-
13:55
debate: optimal approach for the management of cll patients with del(17p) - novel agents
-
15:23
debate: optimal approach for the management of cll patients with del(17p) - ibrutinib
-
14:21
debate: which is the optimal approach for cll? - fcr
-
27:18
novel treatment options in cll
-
6:28
ibrutinib for cll with deletion 17p
-
25:38
cll: chemotherapy and ibrutinib based regimens
-
25:09
cll: long-term updates on ibrutinib and idelalisib
-
12:08
debate: which is the optimal approach for cll? - br
-
24:17
combination of novel agents in cll: is this the final answer?
-
16:07
treatment strategies for relapsed/refractory cll
-
24:09
update on venetoclax for cll
-
23:32
what's next in cll?
-
21:50
update on venetoclax for cll: how low can you go (mrd)?
-
20:43
venetoclax resistance: mechanisms and treatment options
-
18:49
use of novel prognostic markers in practice for cll
-
22:08
role of chemotherapy in cll management
-
1:18
eha 17: best treatment for chronic lymphocytic leukaemia with 17p deletion - prof michael keating
-
2:09
phase ii trial of venetoclax monotherapy for relapsed/refractory cll with 17p deletion